WILEX AG: Subsidiary Heidelberg Pharma to Present the Proprietary ATAC Technology Platform at the Annual World ADC Summit

• Heidelberg Pharma shortlisted for World Award

Munich, Germany, 20 September 2017 - WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) today announced that its subsidiary, Heidelberg Pharma Research GmbH, Ladenburg, Germany, will present at the 8 Annual World Summit taking place on 20-22 September in San Diego, CA, USA.

This annual summit is expected to draw record attendance from over 650 companies including large and small pharma, biotech, academia as well as CROs, CMOs and industry suppliers that cover every element of Drug Conjugate () development. The World Summit organizes cutting-edge science and transformative insights. Further information can be found at: http://worldadc-usa.com.

Details of the Heidelberg Pharma presentation

Targeted Amanitin Conjugates (ATACs): Expanding the Landscape with a New Payload Targeting RNA Polymerase II
Presenter: Professor Andreas Pahl (Chief Scientific Officer)
Date: Thursday, 21 September 2017, 5:30 PM (CDT)
Venue: Sheraton San Diego Hotel & Marina

Heidelberg Pharma will discuss how Targeted Amanitin Conjugates (ATACs) represent a new class of ADCs using the payload Amanitin, which inhibits RNA polymerase II, a novel mode of action in oncology therapy. The presentation will include improvements in the technology and an update of the HDP-101 development, the first Amanitin loaded directed against B-cell maturation antigens (BCMA) and scheduled to enter trials in Multiple Myeloma by the end of 2018.

Additionally, Heidelberg Pharma has been nominated a finalist for the 4 Annual World Awards in the category 'Best New Drug Developer'. The Award's ceremony takes place on 21 September 2017 in the Bel Aire Ballroom of the Sheraton San Diego Marina at 7:15 PM (CDT).

About Heidelberg Pharma's proprietary ATAC technology
-drug conjugates (ADCs) combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer. Targeted Amanitin Conjugates (ATACs) are ADCs whose active ingredient is made up of amatoxin molecules. Amatoxins are small bicyclic peptides naturally occurring in the death cap mushroom. They inhibit mRNA transcription by binding to RNA polymerase II, a mechanism that is crucial for the survival of eukaryotic cells. In preclinical testing, ATACs have been shown to be highly efficacious, overcoming frequently encountered resistance mechanisms and combatting even quiescent tumor cells.

About WILEX
WILEX AG is a biopharmaceutical company based in Munich, Germany, that serves as a parent and holding company. The Company's research and development work is conducted by its subsidiary Heidelberg Pharma Research GmbH in Ladenburg. Heidelberg Pharma is the first company to develop the toxin Amanitin into cancer therapies using its proprietary Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the company's own therapeutic ATACs as well as in third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA-ATAC for multiple myeloma. WILEX's clinical assets MESUPRON and REDECTANE have been partnered, while RENCAREX is available for out-licensing and further development. WILEX is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / Symbol WL6. More information is available at www.wilex.com.

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as 'estimates', 'believes', 'expects', 'may', 'will', 'should', 'future', 'potential' or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

Seite gelesen: 2 | Heute: 2